Regend Therapeutics Gains NMPA Approval for Phase I/II Study of REGEND003 in Diabetes-Related CKD
Suzhou-based stem cell therapy specialist Regend Therapeutics announced that it has received approval from China’s...
Regend Therapeutics
Regend Therapeutics’ Pulmovinci Receives FDA Orphan Drug Designation for IPF
Suzhou-based stem cell therapy specialist Regend Therapeutics announced that the US Food and Drug Administration...